A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy

Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Report...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragoonanan, Dristhi, Bhar, Saleh, Mohan, Gopi, Beltramo, Fernando, Khazal, Sajad J., Hurley, Caitlin, Andersen, Clark, Margossian, Steven, Neelapu, Sattva S., Shpall, Elizabeth, Gutierrez, Cristina, Tewari, Priti, Shoberu, Basirat, Talleur, Aimee, McCall, David, Nunez, Cesar, Cuglievan, Branko, Tambaro, Francesco Paolo, Petropoulos, Demetrios, Abdel-Azim, Hisham, Mahadeo, Kris M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638171/
https://www.ncbi.nlm.nih.gov/pubmed/36353531
http://dx.doi.org/10.3389/fonc.2022.1022901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638171/
https://www.ncbi.nlm.nih.gov/pubmed/36353531
http://dx.doi.org/10.3389/fonc.2022.1022901

Ejemplares similares